Norditropin Daily denied as non-formulary by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Denies Norditropin as Non-Formulary

UnitedHealthcare places somatropin products on its formulary at specific tier levels, and Norditropin (somatropin injection, Novo Nordisk) may not appear on your plan's specific formulary or may require a formulary exception. A non-formulary denial does not mean the drug is not medically appropriate — it means the plan's benefit design defaults to other options. You have a clear path to appeal through a formulary exception process.

## Why This Denial Is Appealable

Under federal law (ACA and CMS rules for non-grandfathered plans), you have the right to request a formulary exception when your prescriber determines that formulary alternatives are contraindicated, have been tried and failed, or are otherwise not clinically appropriate for your specific situation. If your prescriber documents that Norditropin is medically necessary and that formulary alternatives are inadequate, UHC is required to consider granting the exception.

## Federal Appeal Framework

• Formulary exception request: File this first — it is a distinct pre-appeal step. Your prescriber submits clinical justification explaining why Norditropin is necessary over any formulary somatropin product.
• Internal appeal: If the exception is denied, you have the right to a full-and-fair internal appeal under ERISA §503 or applicable state law.
• External review: Under ACA §2719, a final internal denial is subject to binding independent external review. File within the external-review window (generally four months from the denial date).
• Expedited option: Request expedited processing if a delay would seriously jeopardize your health.

## Concrete Appeal Steps and Timeline

1. Confirm which somatropin products are on your plan's formulary and at what tier by requesting UHC's current formulary or checking your benefits portal. 2. Ask your prescriber to document in writing the clinical reason(s) Norditropin is specifically required — device preference, delivery system tolerability, or documented inadequacy of formulary alternatives. 3. Submit a formulary exception request with this documentation. 4. If denied, file a formal internal appeal, including the exception denial and the prescriber letter. 5. Escalate to external review if the internal appeal fails.

## Documentation to Gather

• Formulary comparison: A list of formulary somatropin alternatives and a prescriber statement addressing why each is clinically suboptimal or has already failed for this patient.
• Prior-use history: Dates and outcomes for any formulary somatropin products previously trialed, if applicable.
• Device/delivery rationale: If Norditropin's delivery device (NordiFlex, NordiPen) is clinically important — for example, for a pediatric patient or a patient with dexterity limitations — document this specifically.
• Prescriber medical-necessity letter: Must state the FDA-approved indication, clinical reasoning for Norditropin specifically, and why formulary substitution is not appropriate.

## Criteria-Mapping Structure

Obtain UHC's formulary exception criteria from your denial letter or the plan's published formulary exception policy. Then build a point-by-point response:

| Exception Criterion | Supporting Evidence | |---|---| | [Copy criterion verbatim from UHC policy or denial letter] | [Prescriber note, trial record, or device rationale from the chart] |

Address every criterion. Attach the prescriber letter, the prior-trial records, and the completed table to both the exception request and any subsequent appeal.